Shima, T., Nagafuji, K., Miyamoto, T., Ota, S., Katsuoka, Y., Yoshihara, S., Uchida, N., Kasahara, S., Hosoi, H., Watanabe, M., Uchiyama, H., Kanda, J., Asano, T., Nawa, Y., Takase, K., Satake, A., Kuroda, J., Eto, T., Imamura, Y., Miyazaki, Y., Mori, A., Yamamoto, S., Nagashima, T., Masuda, S., Nakae, Y., Minamiguchi, H., Katayama, Y., Ishikawa, T., Fujii, S., Fujisaki, T., Takenaka, K., Yoshimoto, G., Choi, I., Ogata, M., Kato, K., Harada, N., Kuroiwa, M., Onozawa, M., Yamamoto, H., Kitagawa, J., Tsukamoto, T., Asada, N., Imanaka, R., Tanimoto, K., Yoshida, S., Semba, Y., Kikushige, Y., Ito, Y., Maeda, T., Akashi, K. (2025). Efficacy of upfront blinatumomab combined with reduced-intensity chemotherapy for newly diagnosed adult Philadelphia chromosome–negative B-lineage acute lymphoblastic leukemia: Interim analysis of two prospective studies of JSCT ALL/MRD2023 and ALL/MRD2019 in Japan. Blood. https://doi.org/10.1182/blood-2025-5116